Hydroxocobalamin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Hydroxocobalamin
- Hydroxocobalamin: From Vitamin B12 Deficiency / Cyanide Poisoning to Esophageal Varices Without Bleeding
Hydroxocobalamin: From Vitamin B12 Deficiency / Cyanide Poisoning to Esophageal Varices Without Bleeding
One-Sentence Summary
Hydroxocobalamin is the active form of vitamin B12, established for treating B12 deficiency and as a cyanide-poisoning antidote. The TxGNN model predicts potential efficacy for Esophageal Varices Without Bleeding with a 99.23% prediction score, but currently no clinical trials and no literature support this direction — the prediction is based purely on knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin B12 deficiency / cyanide poisoning (based on known pharmacology; no formal Taiwan license data available) |
| Predicted New Indication | Esophageal Varices Without Bleeding |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Note: A near-identical prediction exists for Esophageal Varices With Bleeding (score 99.23%, rank 6146), also with no supporting trials or literature and a Hold recommendation.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a High-severity data gap). Based on known pharmacology, hydroxocobalamin's established mechanisms are cyanide detoxification (binding cyanide ions to form cyanocobalamin, excreted renally) and correction of B12 deficiency (coenzyme function in methionine/succinyl-CoA metabolism).
Esophageal varices arise from portal hypertension secondary to cirrhosis, involving changes in vessel wall tension and fragility. No pharmacological literature currently establishes a direct mechanistic link between the B12/cobalamin pathway and portal pressure regulation or esophageal vessel wall integrity.
The high TxGNN score (99.23%) most likely reflects an indirect knowledge-graph association — for example, the comorbidity relationship between B12 deficiency (e.g., pernicious anemia) and liver disease — rather than a causal pharmacological mechanism. This is a model-generated hypothesis that requires manual biological plausibility review before further investment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
This drug is currently not marketed in Taiwan (0 authorizations on record), so no license/product information is available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any S1 safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5, decision stage S0) with zero clinical trials, zero literature, and no established mechanistic rationale linking B12/cyanide pathways to portal hypertension or variceal pathology. Combined with a Blocking safety data gap and the drug's unmarketed status in Taiwan, there is insufficient basis to advance.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — resolves Blocking gap DG001
- Confirmed mechanism of action via DrugBank — resolves High-severity gap DG002
- Preclinical/mechanistic studies exploring any B12–portal hypertension or vascular wall relationship
- Ongoing surveillance for emerging trials or literature on either esophageal varices indication (with/without bleeding)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.